WELCOME TO LEVIN HEALTH
We are a Melbourne-based, privately held medical cannabis company that has been awarded a cultivation licence from the Australian Office of Drug Control in April 2019. We are progressing development of our licenced facility for the cultivation of medical cannabis flower at our wholly owned property in Gippsland. Off-take agreements are in place with third parties to purchase cannabis biomass, thereby positioning ourselves as a key player in the Australian supply chain.
In addition to our cultivation activities, we will be launching a range of Australian made medical cannabis products under the Levinol TM brand in late 2020, leveraging relationships in place with GMP-certified pharmaceutical manufacturers and specialist distribution companies to ensure a rapid path to market.
In parallel, we will be launching our clinical trial activities targeting selected patient groups, to launch clinically-validated medical cannabis-based products.
Our strong industry relationships and focus on clinically validated products position us to become one of Australia’s leading medical cannabis organisations.
WHY USE CANNABIS?
Cannabis contains 483 known compounds, including at least 65 cannabinoids. The most well-known of these is tetrahydrocannabinol or THC, which is known for psychoactive effects. Additionally, one of the most beneficial and widely researched cannabinoids in cannabis is Cannabidiol or CBD, which produces no psychoactive effect.
THC and CBD specifically act upon the CB1 and CB2 receptors located throughout the bodies endocannabinoid system. Studies suggest this system plays a large role in regulating stress recovery, protecting our nervous system, activating our immune system response and regulating our homeostatic balance. Medication derived from cannabis including THC and CBD extracts can play a role in providing relief from chronic pain, arthritis, nausea, stress, anxiety and depression; as well as enhancing brain function, vascular health, bone density and helping to combat Asthma.
PRODUCTS UNDER DEVELOPMENT
We have plans to clinically test our formula with our partners to aid in treating chronic pain and inflammation.
Our Mission is to develop medicinal cannabis products that are backed by clinical evidence and noticeably enhance the lives of patients and cannabis users worldwide.
Board of Directors
Mr Syme is a Chartered Accountant and an accomplished corporate executive with over 30 years’ experience in senior management roles in Australia and overseas. He has been MD, CEO or CFO of several successful ASX and LSE listed companies in the materials, technology and media sectors.
B.Eng Chemical (Hons), B.B.M
Levent is a founder and major shareholder of the Company and was responsible for securing the Company’s cannabis cultivation licence.
Mr Wheeler has over 30 years experience in senior executive and corporate advisory roles in Australia and overseas. He has been a director, executive or adviser to a range of public and private concerns in the resources, energy, technology and industrial sectors.
Dr. Ismail Gulec
Founding Shareholder & Technical Officer
Dr. Ismail is an active environmental scientist with significant experience in the industry. His works include a research PhD in environmental science as well as multiple international research publications.He works as a Principal Toxicologist and Risk Assessor for a major environmental risk consultancy.
Alistair Barkhouse graduated with a Bachelor of Science with a major in Agriculture at the University of Western Australia Alistair has 25 years of experience in the healthcare industry, including much experience with start-up companies in driving their sales and distribution results. Alistair’s sales experience includes over 13 years at global pharmaceutical company, Bristol Myers Squibb where Alistair was the Director of Commercial Operations.
Harry is a pioneer of the Australian medical cannabis sector and has been directly involved in the founding of multiple companies including AusCann, Zelda Therapeutics, CannPal Animal Therapeutics, CliniCann and HealthHouse.
He graduated from The University of Western Australia with Bachelors and Honours in Science majoring in Biochemistry and Microbiology as well as a Masters in Business Administration. He also holds several post-graduate qualifications in business and finance.
Brian is an experienced senior business executive with highly developed commercial acumen and a unique combination of commercial skills in the pharmaceuticals industry combined with a strong finance background.
Brian was previously a business development manager for bioCSL and for AHG, responsible for strategy development and business planning.
As a director of BPPR Consulting Brian has managed the development of a number projects within the pharmaceuticals industry
James is a well known television and radio broadcaster, with over 30 years experience as a journalist and sports caller. James was previously a professional first class cricketer in Australia and England and was Chairman of the North Melbourne Football Club from 2008 to 2016. His background has given him valuable insight into the lives of former athletes and the urgent need to find non-addictive pain relief alternatives.
An expert in the field of compounding medicines, Mark was one of the first practitioners in Australia managing and owning a specialist practice. He has extensive experience in setting Pharmacy Practice Standards in the field, being a member of the Therapeutic Goods Administration Pharmacy Manufacturing Technical Expert Reference Group (PM-TERG). Mark is a past President of the Victorian Branch of the Pharmaceutical Society of Australia, holding this position from 2008 to 2012; and Chair of the Professional Development Committee PSA (Vic) from 2006 to 2016.
Michael is an innovative serial entrepreneur with ventures in agriculture/horticulture, high-tech manufacturing and alternative energy. He has operated in Canada, the United States, China (including Hong Kong), Africa and Japan. Over the past two decades, Mike has designed and operated numerous cannabis production facilities, ranging from 100 to 11,000 flowering plants; establishing state-of-the-art cannabis cultivation standards used all over the world.